Avelox approved for resistant pneumonia strains
Executive Summary
Bayer Avelox (moxifloxacin) receives supplemental approval for the treatment of community acquired pneumonia caused by multi-drug resistant Streptococcus pneumoniae May 18. Avelox had been approved to treat mild to moderate community acquired pneumonia. The product is the first antibiotic available in both I.V. and tablets to treat those strains, the company said. Oscient Pharmaceuticals' Factive (gemifloxacin) and Aventis' Ketek (telithromycin), which are available in tablets, also have indications for the strains...